Sprintome
@sprintome.bsky.social
AI + Drug Discovery | Your front-row seat to the future of medicine
https://sprintome.substack.com
https://sprintome.substack.com
Pinned
Sprintome
@sprintome.bsky.social
· Apr 18
AI is no longer just a tool in the lab — it's becoming the lab.
At NVIDIA #GTC, the future of drug discovery was laid bare: computational, agentic, and lightning fast. Here's what you need to know 👇
At NVIDIA #GTC, the future of drug discovery was laid bare: computational, agentic, and lightning fast. Here's what you need to know 👇
🔥 Arsenal Biosciences slashes workforce by 50% to optimize resources. CEO Ken Drazan confirms the major move by the well-funded cell therapy startup. Restructuring aims to enhance focus on core initiatives.
September 18, 2025 at 3:24 PM
🔥 Arsenal Biosciences slashes workforce by 50% to optimize resources. CEO Ken Drazan confirms the major move by the well-funded cell therapy startup. Restructuring aims to enhance focus on core initiatives.
City Therapeutics receives significant early-stage funding for their novel application of cityRNAs in siRNA therapeutics. Nature Biotechnology highlights their innovative strategy in the biotech sector.
September 18, 2025 at 11:31 AM
City Therapeutics receives significant early-stage funding for their novel application of cityRNAs in siRNA therapeutics. Nature Biotechnology highlights their innovative strategy in the biotech sector.
🏆 Regeneron triumphs with phase 3 success in ultrarare disease, fueling FDA race. Garetosmab for fibrodysplasia ossificans progressiva set for approval filing by end of 2025 after pivotal trial victory.
September 18, 2025 at 11:12 AM
🏆 Regeneron triumphs with phase 3 success in ultrarare disease, fueling FDA race. Garetosmab for fibrodysplasia ossificans progressiva set for approval filing by end of 2025 after pivotal trial victory.
💰 Ollin Biosciences launches with $100M, aiming to challenge Roche's eye disease dominance. Co-founder Jason Ehrlich, once at Genentech, now leads the charge with a Chinese-sourced antibody. A showdown is on the horizon!
September 18, 2025 at 10:55 AM
💰 Ollin Biosciences launches with $100M, aiming to challenge Roche's eye disease dominance. Co-founder Jason Ehrlich, once at Genentech, now leads the charge with a Chinese-sourced antibody. A showdown is on the horizon!
💰 GSK unveils massive $30B investment plan for U.S. R&D and manufacturing. British pharma giant joins American investment wave. Major boost for the industry and economy!
September 18, 2025 at 12:48 AM
💰 GSK unveils massive $30B investment plan for U.S. R&D and manufacturing. British pharma giant joins American investment wave. Major boost for the industry and economy!
Affini-T Therapeutics faces potential shutdown as CEO departs. Last senior executive's exit raises questions about company's future. Biotech's focus on cell therapies for solid tumors now in jeopardy.
September 18, 2025 at 12:47 AM
Affini-T Therapeutics faces potential shutdown as CEO departs. Last senior executive's exit raises questions about company's future. Biotech's focus on cell therapies for solid tumors now in jeopardy.
🌟 Eli Lilly's orforglipron outperforms Novo Nordisk's Rybelsus in diabetes trial! Lilly considers fast-track filing for its obesity pill. Exciting developments in the competitive diabetes market.
September 18, 2025 at 12:43 AM
🌟 Eli Lilly's orforglipron outperforms Novo Nordisk's Rybelsus in diabetes trial! Lilly considers fast-track filing for its obesity pill. Exciting developments in the competitive diabetes market.
💰 Dualitas secures a whopping $65M in venture capital funding, while AllRock raises a solid $50M. The Fierce Biotech Fundraising Tracker highlights major investments in biotech.
September 16, 2025 at 7:59 PM
💰 Dualitas secures a whopping $65M in venture capital funding, while AllRock raises a solid $50M. The Fierce Biotech Fundraising Tracker highlights major investments in biotech.
🚨 FDA flags AstraZeneca's flu vaccine TV ad in regulatory crackdown. Letter dated Sept. 9 calls out 60-second FluMist ad for misleading claims. Part of wider scrutiny on pharma commercials.
September 16, 2025 at 12:39 PM
🚨 FDA flags AstraZeneca's flu vaccine TV ad in regulatory crackdown. Letter dated Sept. 9 calls out 60-second FluMist ad for misleading claims. Part of wider scrutiny on pharma commercials.
💰 AstraZeneca halts $271M expansion in UK, joining other Big Pharma companies scaling back in Britain. The decision impacts the Cambridge research site, reflecting a broader trend in the industry.
September 16, 2025 at 12:38 AM
💰 AstraZeneca halts $271M expansion in UK, joining other Big Pharma companies scaling back in Britain. The decision impacts the Cambridge research site, reflecting a broader trend in the industry.
HHS Secretary Robert F. Kennedy Jr. has added 5 new members to the Advisory Committee on Immunization Practices in preparation for an upcoming critical meeting. The panel's decisions could have significant implications for immunization strategies.
September 15, 2025 at 11:07 PM
HHS Secretary Robert F. Kennedy Jr. has added 5 new members to the Advisory Committee on Immunization Practices in preparation for an upcoming critical meeting. The panel's decisions could have significant implications for immunization strategies.
📉 aTyr Pharma's stock plummets 80% after Phase 3 failure in pulmonary sarcoidosis trial. Investor confidence shaken as {$ATYR} shares crash at market open. Company faces challenges ahead.
September 15, 2025 at 11:03 PM
📉 aTyr Pharma's stock plummets 80% after Phase 3 failure in pulmonary sarcoidosis trial. Investor confidence shaken as {$ATYR} shares crash at market open. Company faces challenges ahead.
💰 Galimedix gears up for phase 2 funding round as oral Alzheimer's candidate passes safety test. Small molecule shows no serious adverse events and penetrates blood-brain barrier successfully. Maryland-based biotech poised for next stage of development.
September 15, 2025 at 10:44 PM
💰 Galimedix gears up for phase 2 funding round as oral Alzheimer's candidate passes safety test. Small molecule shows no serious adverse events and penetrates blood-brain barrier successfully. Maryland-based biotech poised for next stage of development.
💰 Novartis seals $120M deal with Monte Rosa Therapeutics for immune degraders. Swiss pharma giant's deal spree continues, with total biobucks value exceeding $5.7B. Partnership set to advance innovative therapies.
September 15, 2025 at 10:44 PM
💰 Novartis seals $120M deal with Monte Rosa Therapeutics for immune degraders. Swiss pharma giant's deal spree continues, with total biobucks value exceeding $5.7B. Partnership set to advance innovative therapies.
🚨 US government criticizes mRNA vaccine research in recent report. Findings published in Nature Biotechnology highlight concerns. Impact on future funding and regulatory decisions uncertain.
September 15, 2025 at 10:40 PM
🚨 US government criticizes mRNA vaccine research in recent report. Findings published in Nature Biotechnology highlight concerns. Impact on future funding and regulatory decisions uncertain.
💸 FibroGen settles with SEC for $1.25M over claims ex-exec altered roxadustat data. Former CMO accused of data manipulation for anemia drug. Company takes action to address allegations.
September 13, 2025 at 7:35 PM
💸 FibroGen settles with SEC for $1.25M over claims ex-exec altered roxadustat data. Former CMO accused of data manipulation for anemia drug. Company takes action to address allegations.
🚀 Exact Sciences launches Cancerguard multi-cancer blood test priced at $689. Initially available to physicians, wider consumer access through telehealth portal next month will revolutionize early cancer detection.
September 13, 2025 at 6:58 PM
🚀 Exact Sciences launches Cancerguard multi-cancer blood test priced at $689. Initially available to physicians, wider consumer access through telehealth portal next month will revolutionize early cancer detection.
Jake Leach will transition to CEO of Dexcom in 2026, replacing Kevin Sayer after a 10-year tenure. Smooth leadership succession plan in place for the diabetes tech company.
August 3, 2025 at 7:12 PM
Jake Leach will transition to CEO of Dexcom in 2026, replacing Kevin Sayer after a 10-year tenure. Smooth leadership succession plan in place for the diabetes tech company.
Following the departure of Lars Fruergaard Jørgensen, Novo Nordisk appoints Maziar Mike Doustdar as the new CEO. Doustdar, currently EVP of international operations, will take the helm on Aug. 7 after the company's half-year report.
August 3, 2025 at 5:56 PM
Following the departure of Lars Fruergaard Jørgensen, Novo Nordisk appoints Maziar Mike Doustdar as the new CEO. Doustdar, currently EVP of international operations, will take the helm on Aug. 7 after the company's half-year report.
AbbVie is reportedly considering a $1B acquisition of Gilgamesh to enhance its neuroscience portfolio. This move complements its strong sales performance with Skyrizi and Rinvoq. Strategic business development in action.
August 3, 2025 at 5:51 PM
AbbVie is reportedly considering a $1B acquisition of Gilgamesh to enhance its neuroscience portfolio. This move complements its strong sales performance with Skyrizi and Rinvoq. Strategic business development in action.
Ultromics raises $55M to expand in the U.S. and improve cardiovascular disease detection accuracy. CEO Ross Upton highlights the focus on new AI modules. Exciting developments ahead!
August 3, 2025 at 2:08 PM
Ultromics raises $55M to expand in the U.S. and improve cardiovascular disease detection accuracy. CEO Ross Upton highlights the focus on new AI modules. Exciting developments ahead!
A program supported by Big Pharma and the NIH foundation is launching to promote alternatives to animal testing in drug development.
August 3, 2025 at 12:14 PM
A program supported by Big Pharma and the NIH foundation is launching to promote alternatives to animal testing in drug development.
A new Caribbean company, Excalipoint, has entered the T-cell engager arena by striking a significant deal with Lepu Biopharma. The $857M agreement includes an initial payment of $10M for two preclinical assets. Stay tuned for developments in this rapidly evolving space.
August 2, 2025 at 7:54 PM
A new Caribbean company, Excalipoint, has entered the T-cell engager arena by striking a significant deal with Lepu Biopharma. The $857M agreement includes an initial payment of $10M for two preclinical assets. Stay tuned for developments in this rapidly evolving space.
Baxter faces a stock drop of over 20% post financial forecast cut and infusion pump shipment pause. The company is slowly recovering from Hurricane Helene's impact. A challenging period ahead for Baxter. 📉💼
August 2, 2025 at 7:50 PM
Baxter faces a stock drop of over 20% post financial forecast cut and infusion pump shipment pause. The company is slowly recovering from Hurricane Helene's impact. A challenging period ahead for Baxter. 📉💼
A new initiative, the Validation and Qualification Network, aims to shift drug development away from animal testing. This program, supported by various partners, will review proposals until Dec. 31. The focus is on reducing, replacing, or refining the use of live animals in research.
August 2, 2025 at 12:01 AM
A new initiative, the Validation and Qualification Network, aims to shift drug development away from animal testing. This program, supported by various partners, will review proposals until Dec. 31. The focus is on reducing, replacing, or refining the use of live animals in research.